CV Sciences (CVSI) AI Stock Analysis

• Market Cap: $7.84M
• Dividend Yield: N/A
• Average Volume (3M): 246.65K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.32
• Revenue Growth: -8.04%
• EPS Growth: 47.02%
• Country: US
• Employees: 47
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): >-0.01
• Shares Outstanding: 184,263,660
• 10 Day Avg. Volume: 158,629
• 30 Day Avg. Volume: 246,649
• PEG Ratio: 0.01
• Price to Book (P/B): 3.31
• Price to Sales (P/S): 0.38
• P/FCF Ratio: -6.75
• Enterprise Value/Market Cap: 1.06
• Enterprise Value/Revenue: 0.75
• Enterprise Value/Gross Profit: 1.23
• Enterprise Value/Ebitda: -9.53
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 47 Neutral
• Price Target: $0.05 ▼(-47.78% Downside)

The score is held back primarily by weak fundamentals—sharp revenue contraction, ongoing losses, and thin/negative free cash flow—despite some margin improvement and manageable leverage. Technical indicators are neutral with modest positive momentum, but valuation remains unattractive due to negative earnings, and the latest company update highlights regulatory and demand pressures even as it pursues product launches and growth initiatives.

Positive Factors

Product Innovation

The introduction of new products can drive organic growth by expanding the product line and attracting new customers, enhancing long-term revenue potential.

Gross Margin Stability

Stable gross margins indicate effective cost management and pricing strategies, which are crucial for sustaining profitability over time.

Strategic M&A Opportunities

Exploring M&A opportunities can lead to strategic growth, market expansion, and increased shareholder value, supporting long-term business development.

Negative Factors

Declining Revenue

A declining revenue trend can indicate weakening market demand or competitive pressures, potentially impacting long-term financial health and growth prospects.

Negative Cash Flow

Negative cash flow suggests difficulties in generating sufficient cash from operations, which can hinder investment in growth opportunities and strain liquidity.

High Leverage Risk

High leverage can increase financial risk, limit flexibility, and lead to higher interest expenses, affecting the company's ability to invest in future growth.

CV Sciences Business Overview & Revenue Model

Company Description

CV Sciences, Inc. (CVSI) is a biotechnology company focused on the research, development, and commercialization of products derived from hemp extract, particularly those containing cannabidiol (CBD). Operating primarily in the wellness and pharmaceutical sectors, CV Sciences offers a range of products including dietary supplements, topical applications, and pharmaceutical formulations aimed at promoting health and well-being. The company is dedicated to providing high-quality, science-backed products that leverage the therapeutic potential of cannabinoids.

How the Company Makes Money

CV Sciences generates revenue through multiple streams, primarily by selling its consumer products under the brand name PlusCBD Oil. This includes a variety of CBD-infused dietary supplements, oils, and topical products which are sold through various channels such as retail stores, e-commerce platforms, and direct-to-consumer sales. Additionally, CV Sciences is engaged in the development of pharmaceutical products, particularly focusing on prescription medications that utilize CBD for therapeutic purposes. The company benefits from strategic partnerships with retailers and health product distributors, which help expand its market reach. Furthermore, the growing consumer interest in CBD products and the increasing legalization of hemp-derived products across various jurisdictions contribute to the company's revenue growth.

CV Sciences Financial Statement Overview

Summary

Financial performance is weak: TTM revenue fell sharply (-25.81%) and the company remains unprofitable (negative EBIT and net margins). Margins improved and losses narrowed versus 2024, and leverage is not excessive, but cash generation remains very limited (TTM operating cash flow ~$0.04M; free cash flow negative), keeping overall fundamentals pressured.

Income Statement

TTM (Trailing-Twelve-Months) revenue declined sharply (-25.81%), indicating meaningful top-line pressure. Profitability has improved versus 2024 (losses narrowing, with gross margin expanding to ~60.8% from ~45.6%), but the company is still unprofitable with negative operating and net margins (EBIT margin ~-9.4%, net margin ~-13.3%). Results show volatility: strong profitability in 2023 was followed by losses in 2024 and continued losses in TTM, which lowers confidence in earnings durability.

Balance Sheet

Leverage is moderate in TTM, with debt-to-equity around 0.56 and total debt of $0.86M against $1.54M of equity, suggesting debt is not currently excessive. However, equity has shrunk from 2023 levels, and returns on equity remain negative in TTM, reflecting ongoing losses. The balance sheet also shows historical instability (including a period of negative equity in 2022), which remains a risk factor even though equity is positive today.

Cash Flow

Cash generation is weak and inconsistent. TTM operating cash flow is only $0.04M and free cash flow is negative (-$0.07M), following materially negative operating and free cash flow in 2024. While cash flow improved substantially from 2024 to TTM, the current level of operating cash flow provides very limited support for the income statement and suggests the business is still not consistently self-funding.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	11.11M	15.71M	16.00M	16.20M	20.05M	24.43M
Gross Profit	6.76M	7.17M	7.08M	5.55M	8.62M	11.01M
EBITDA	-873.00K	-1.86M	3.85M	-5.66M	-14.00M	-21.72M
Net Income	-1.48M	-2.39M	3.10M	-8.21M	-15.55M	-22.28M
Balance Sheet
Total Assets	7.00M	7.93M	26.35M	12.74M	18.07M	30.63M
Cash, Cash Equivalents and Short-Term Investments	381.00K	454.00K	1.32M	611.00K	1.38M	4.02M
Total Debt	860.00K	779.00K	442.00K	1.53M	922.00K	7.77M
Total Liabilities	5.46M	6.13M	23.44M	13.51M	14.52M	19.41M
Stockholders Equity	1.54M	1.79M	2.90M	-777.00K	3.54M	11.21M
Cash Flow
Free Cash Flow	-65.00K	-879.00K	2.25M	-1.89M	-7.52M	-8.36M
Operating Cash Flow	42.00K	-861.00K	2.25M	-1.89M	-7.49M	-7.30M
Investing Cash Flow	-122.00K	-28.00K	-156.00K	0.00	-35.00K	-1.06M
Financing Cash Flow	-256.00K	32.00K	-1.39M	1.12M	4.37M	3.27M

CV Sciences Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 0.09
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CVSI, the sentiment is Neutral. The current price of 0.09 is above the 20-day moving average (MA) of 0.05, above the 50-day MA of 0.04, and above the 200-day MA of 0.04, indicating a neutral trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 45.04 is Neutral, neither overbought nor oversold. The STOCH value of 29.30 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for CVSI.

CV Sciences Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
FLGC	50 Neutral	$27.69M	-0.35	-37.38%	―	-22.60%	53.82%
YCBD	49 Neutral	$10.92M	-0.27	-44.42%	―	-1.50%	80.17%
CVSI	47 Neutral	$7.84M	-5.25	-79.25%	―	-8.04%	47.02%
IXHL	47 Neutral	$107.19M	-0.29	-114.52%	―	-86.05%	24.17%
IMCC	40 Underperform	$6.82M	-1.65	-93.87%	―	-0.74%	81.49%
COSM	40 Underperform	$17.98M	-0.68	-63.82%	―	―	―

CV Sciences Corporate Events

CV Sciences Reports Q3 2025 Financial Results

On November 13, 2025, CV Sciences reported its financial results for the third quarter of 2025, showing a revenue of $3.3 million, a decline from the previous year due to lower sales volume and regulatory challenges. Despite the revenue drop, the company maintained a healthy gross margin of 48.5% and introduced new products, aiming for organic growth and strategic M&A opportunities to enhance revenue and shareholder value. The company also addressed recent legislative changes affecting the hemp industry, expressing disappointment but seeing an opportunity to influence future regulations.